
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Enova International, you have to buy into a digital lender that is comfortable operating in under-served, higher-risk credit pockets and using data to price that risk. The latest earnings beat, with revenue, EBITDA and EPS all ahead of expectations, reinforces the near term catalyst around growth in non-prime consumer and small business lending in the US and Brazil, and helps explain the strong share price move over the past quarter. At the same time, the stock is already priced above some cash flow based estimates and trades at a premium to many consumer finance peers, so this result may not dramatically change valuation debates, but it does support confidence in the current earnings trajectory. The bigger question is how that growth interacts with Enova’s high leverage and regulatory exposure.
But the same leverage that boosts returns can also increase vulnerability if conditions change. Enova International's share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.Explore 4 other fair value estimates on Enova International - why the stock might be worth as much as 98% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com